Jan 10, 2023 / 06:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with Denali. Little change from last time we were here in person. We're not going to switch rooms for Q&A. We're going to go seamlessly into Q&A after the presentation. You can raise your hand and someone will bring you a microphone or you can enter your question electronically on the portal, I'll send it to an iPad up there, and I can ask the management team.
So with that, let me pass it over to Denali's CEO of Ryan Watts.
Ryan J. Watts - Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
Thank you, Jess. It's great to be back in person. It's great to see so many familiar faces, friends collaborators and friendly competitors looking forward to dive into some data today for our programs. It's such an exciting time to be in biotech. Actually, it's a very exciting time to be in neuroscience in
Denali Therapeutics Inc at 41st Annual J.P. Morgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers